These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4428416)

  • 21. [Radiometric determination of capillary permeability and tissue circulation in patients with coronary atherosclerosis treated with heparin].
    Aleĭnikova LI; Dubovyĭ ED; Sokolov VN; Kudlaĭ VR
    Klin Med (Mosk); 1972 Oct; 50(10):42-5. PubMed ID: 4656248
    [No Abstract]   [Full Text] [Related]  

  • 22. [Blood coagulation system in patients with hypertensive disease and atherosclerosis with circulatory insufficiency].
    Andrushchenko EV
    Vrach Delo; 1969 Feb; 2():19-21. PubMed ID: 5779379
    [No Abstract]   [Full Text] [Related]  

  • 23. [Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy].
    Raby C
    Presse Med (1893); 1969 Jan; 77(1):17-9. PubMed ID: 5785756
    [No Abstract]   [Full Text] [Related]  

  • 24. [The thrombotest in hypertension and atherosclerosis].
    Pinkus SSh
    Vrach Delo; 1967 Mar; 3():134-5. PubMed ID: 5609271
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of various laboratory tests in the control of anticoagulant therapy].
    Molinas FC; Sanchez Avalos JC
    Medicina (B Aires); 1967; 27(2):107-15. PubMed ID: 5600645
    [No Abstract]   [Full Text] [Related]  

  • 26. Heparin resistance in relation to hyperlipidemia and hypercoagulability in atherosclerotic diabetics and non-diabetics.
    Higazi AM; el-Ebrashy N; Aly AM; el-Din AS
    J Egypt Med Assoc; 1972; 55(8):577-94. PubMed ID: 4658037
    [No Abstract]   [Full Text] [Related]  

  • 27. [Arteriosclerosis as a main factor in blood coagulation disorders in patients with hypertensive disease].
    Dashtaiants GA; Andrushchenko EV
    Vrach Delo; 1973 Jan; 1():14-6. PubMed ID: 4722275
    [No Abstract]   [Full Text] [Related]  

  • 28. [Recognition of the patient with high risk of thrombosis. Possibilities and limitations of clinical and laboratory tests].
    Nenci GG
    Minerva Med; 1980 Nov; 71(47):3511-22. PubMed ID: 7005755
    [No Abstract]   [Full Text] [Related]  

  • 29. [Takata-Ara and Weltmann's reactions in patients over 50 with hypertensive disease and coronary arteriosclerosis].
    Fesenko IP
    Vrach Delo; 1973 Jun; 6():33-5. PubMed ID: 4755126
    [No Abstract]   [Full Text] [Related]  

  • 30. [Study on the relationship between changes of blood lipids and the fibrinolytic picture in ambulatory patients with arteriosclerosis].
    Rugginenti A
    Minerva Med; 1974 May; 65(34):1873-7. PubMed ID: 4842771
    [No Abstract]   [Full Text] [Related]  

  • 31. [Present state of heparin therapy].
    Blatrix C; Soulier JP; Vacheron A; Cornu P
    Presse Med (1893); 1969 Mar; 77(15):553-6. PubMed ID: 5796027
    [No Abstract]   [Full Text] [Related]  

  • 32. Circulating platelet aggregates: absence of correlation with tests of thrombophilia in aged arteriosclerotic patients.
    Casale G; Ravecca D
    Haematologica; 1981 Aug; 66(4):531. PubMed ID: 6797887
    [No Abstract]   [Full Text] [Related]  

  • 33. [Diagnosis of the pre-thrombotic state in cardiovascular diseases].
    Gritsiuk AI
    Vrach Delo; 1971 Mar; 3():8-14. PubMed ID: 5578033
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of low doses of heparin for treatment of aftereffects of thrombosis of retinal vessels and for prevention of recurrence of the disease].
    Nakhabina TP
    Oftalmol Zh; 1975; 30(8):566-9. PubMed ID: 1214964
    [No Abstract]   [Full Text] [Related]  

  • 35. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [On the physiopathology of thrombogenesis and the besis for the treatment of thrombosis].
    van de Loo J
    Med Klin; 1968 Mar; 63(10):361-6. PubMed ID: 5700938
    [No Abstract]   [Full Text] [Related]  

  • 37. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices.
    Ganter MT; Hofer CK
    Anesth Analg; 2008 May; 106(5):1366-75. PubMed ID: 18420846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-thormbin III and heparin clotting times in thrombosis and atherosclerosis.
    O'Brien JR
    Thromb Diath Haemorrh; 1974 Sep; 32(1):116-23. PubMed ID: 4454034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thrombelastogram in patients with coronary arteriosclerosis and auricular fibrillation].
    Tereshchenko OI
    Vrach Delo; 1974 Nov; 0(11):78-9. PubMed ID: 4432481
    [No Abstract]   [Full Text] [Related]  

  • 40. Coagulation changes induced by endotoxin and purified contact activation product.
    Barth P; Zimmermann R
    Thromb Diath Haemorrh; 1972 Oct; 28(2):280-8. PubMed ID: 4639660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.